TrialPath
Recruiting

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

NCT07481357 · Dong-A ST Co., Ltd.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A First-In-Human Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
About this study
The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC. Participants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.
Eligibility criteria
Inclusion Criteria: 1. Patients aged ≥ 19 years 2. Histologically or cytologically documented advanced CLDN18.2+ GC/GEJ adenocarcinoma or advanced CLDN18.2+ PDAC 3. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) 4. Life expectancy ≥12 weeks as judged by the Investigator Exclusion Criteria: 1. Cardiac abnormalities 2. Gastrointestinal abnormalities 3. Active and clinically significant bacterial, fungal, or viral infection, including known hepatitis B virus (HBV), known hepatitis C virus (HCV), known human immunodeficiency virus (HIV). 4. Active systemic infection requiring IV antibiotics therapy.
Study design
Enrollment target: 51 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-05-18
Estimated completion: 2029-02
Last updated: 2026-05-20
Interventions
Drug: DA-3501
Primary outcomes
  • • Maximum Tolerated Dose (MTD) based on Dose-Limiting Toxicities (DLTs) during Cycle 1 (21 days)
  • • Optimal Biological Effective Dose (OBED) Based on best Overall Response Rate (ORR) (42 days)
Sponsor
Dong-A ST Co., Ltd. · industry
Contacts & investigators
ContactJiwon Shin · contact · jiwon_shin@donga.co.kr · 82-2-920-8768
All locations (3)
CHA University Bundang Medical CenterRecruiting
Seongnam, Bundang, South Korea
Seoul National University Bundang HospitalRecruiting
Seongnam, Bundang, South Korea
Severance HospitalRecruiting
Seoul, Seoul, South Korea